All Personal | GenomeWeb

All Personal

The drug pipelines of pharmaceutical companies like AstraZeneca are full of therapeutics being developed for personalized medicine, writes Frank Vinluan at MedCity News. AstraZeneca's Steve Labkoff says that 65 percent of the company's pipeline is personalized medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.